Summit Therapeutics set to begin HARMONi trial of Ivonescimab in EGFR-mutant lung cancer

Summit Therapeutics Inc. has announced a significant milestone in its oncology development efforts, completing patient enrollment for the HARMONi Phase III clinical trial. This pivotal ... Read More